Skip to main content

Advertisement

Table 5 Subgroup analysis. Comparison of the survival after dose reduction versus full dosage in different subgroups analyzed by Kaplan-Meier procedure and Log-Rank test (Chemotherapy (CTX))

From: Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects

  Dosage reduction Log-rank
Yes (≤ 80%) No (100%)  
Mean (Median) survival in months p-value
Age < 65 22.0 (14.6) 17.1 (12.0) .170
≥65 18.8 (14.9) 21.2 (15.8) .764
Sex Male 23.5 (16.0) 18.6 (14.9) .339
Female 17.2 (13.1) 17.4 (12.7) .170
T stage T3 27.8 (26.4) 25.8 (14.9) .525
T4 15.6 (13.8) 14.1 (12.7) .960
Tx 24.3 (10.4) 14.1 (7.7) .273
N stage N0 25.9 (23.6) 30.5 (14.9) .851
N1 20.7 (13.9) 24.1 (12.3) .669
N2 21.3 (26.4) 13.3 (16.7) .024
Nx 20.4 (16.0) 13.2 (7.7) .294
Grading G2 24.1 (17.8) 22.0 (16.1) .570
G3 17.5 (14.5) 10.6 (10.4) .062
Gx 26.8 (26.8) 25.5 (3.0) .808
L stage L0 19.7 (17.8) 30.7 (21.0) .541
L1 23.3 (13.9) 16.9 (17.5) .485
Lx 18.1 (14.8) 16.3 (12.0) .561
V stage V0 28.8 (23.6) 26.9 (21.0) .828
V1 20.3 (13.9) 15.7 (16.7) .311
Vx 16.9 (14.5) 15.9 (11.8) .671
Charlson Score for Comorbidities 6 20.6 (14.8) 19.6 (12.0) .424
7–10 23.3 (15.0) 19.6 (16.1) .632
Oncological resection/Surgery Yes 22.1 (14.9) 23.8 (17.5) .997
No 19.6 (12.9) 12.9 (7.6) .301
No. of CTX lines 1 10.1 (10.4) 8.4 (3.0) .565
2 23.1 (17.9) 23.5 (15.8) .896
3 24.7 (23.6) 16.6 (12.3) .238
Biological CTX Yes 29.4 (26.8) 23.5 (11.8) .371
No 13.2 (13.1) 14.6 (14.9) .823
CTX regimen sequence FOLFOX- > FOLFIRI 22.0 (20.2) 26.5 (17.5) .425
FOLFIRI- > FOLFOX 12.3 (12.3) 16.4 (14.9) .631
FOLFOX 9.7 (12.9) 7.7 (3.6) .829
FOLFIRI 62.3 (90.7) 13.0 (3.9) .300